The main focus of this program is to develop chemical methodologies to define the major components of vaccines for malaria or Leishmania pathogens and other biological products, with special emphasis to the synthetic constructs made in the form of the MAP (multi-antigen peptide) and lipopeptides. In order to accomplish the objectives, the laboratory maintains state-of-the-art technology in separation, compositional and structural analyses of protein, carbohydrates, lipids, and nucleic acids. Facilities and know-how of protein analyses and peptide syntheses are also maintained. Current on-going projects includes: The main focus of this program is to develop chemical methodologies to define the major components of vaccines for malaria or Leishmania pathogens and other biological products, with special emphasis to the synthetic constructs made in the form of the MAP (multi-antigen peptide) and lipopeptides. In order to accomplish the objectives, the laboratory maintains state-of-the-art technology in separation, compositional and structural analyses of protein, carbohydrates, lipids, and nucleic acids. Facilities and know-how of protein analyses and peptide synthesis are also maintained. Current on-going projects includes: 1. Establishment of analytical methodology for the characterization of the MAP (multi-antigen peptide)and the establishment of the chemical synthesis methodology to obtain chemically defined and pure MAP peptides that may be suitable for use as potential vaccine candidates. 2. Establishment of new techniques for covalently linking synthetic peptides to lipopolysaccharide carriers including new covalently bound adjuvants for evaluation of the immunogenicity of malaria peptides. 3. Provides strong support for quality control of peptide or polypeptide products intended for vaccines, diagnostics and therapeutics. 4. Synthesizes chemically defined peptides mimicking parasitic proteins for the study of molecular pathogenesis. Peptide construct may involve the synthesis of a chemically modified peptide structure to enhance activity.

Agency
National Institute of Health (NIH)
Institute
Food and Drug Administration (FDA)
Type
Intramural Research (Z01)
Project #
1Z01BI003013-07
Application #
6293686
Study Section
Special Emphasis Panel (LPBB)
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1999
Total Cost
Indirect Cost